Trial Profile
Botulinum Toxin Type A (BOTOX) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2017
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Urinary incontinence
- Focus Therapeutic Use
- Sponsors Allergan
- 13 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Feb 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 19 Feb 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.